Gregor a fondé Pharmacentric Solutions Ltd à la fin de l'année 2017 pour fournir des services de conseil à l'industrie pharmaceutique spécialisée dans le développement de dispositifs et d'emballages ainsi que dans les stratégies allant du concept initial à l'approvisionnement commercial. Avant cela, Gregor était Senior Design Director chez GSK et expert en matière de Device and Packaging, basé à Ware, au Royaume-Uni.Gregor est un spécialiste de l'appareillage et de l'emballage avec plus de 30 ans d'expérience dans les industries chirurgicale et pharmaceutique. Il a un B.Sc. en design industriel et un M.Sc. En Polymer Science and Engineering et après un troisième cycle en marketing en 1986, il a travaillé pour Smiths Industries Medical Systems spécialisée dans la conception d'équipements chirurgicaux. En 1989, il rejoint l'unité de développement de dispositifs de GSK R & D. Il a travaillé comme directeur du design sur les plates-formes GSK, y compris les dispositifs injectables et respiratoires et l'emballage. En 2009, Greg a rejoint GSK Manufacturing en tant que responsable mondial des emballages techniques, où il était responsable de tous les projets d'emballage technique. Plus récemment, il s'est concentré sur le soutien des lancements de l'Ellipta Inhaler, des appareils d'entraînement respiratoire et sur la recherche et la préparation des stratégies respiratoires et d'emballage de GSK pour les marchés émergents. En 2016, il a représenté GSK au sein du Medicines Manufacturing Industry Partnership et a rédigé et publié la feuille deroute Technology and Innovation pour UK Pharma. Il détient plus de 40 brevets et a présenté de nombreux sujets sur des sujets tels que le Digital, le Patient Centric Design et la cartographie routière Pharma. Gregor est également Fellow de The Packaging Society et représente Pharma au sein du conseil d'administration de TPS et a été juge des prix SDA de la Royal Society of Arts au cours des 18 dernières années.
Aurelio is a Senior Consultant in the European Thought Leadership team based in IQVIA’s London office.
His primary focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse in biosimilars, generics and value added medicines. He is considered a subject matter expert in these areas where he speaks at numerous conferences worldwide, presents to clients and engages in consulting projects in an advisory capacity.
Prior to IQVIA, Aurelio has worked as a strategy consultant in Life Sciences for LEK and Accenture and in R&D for Pfizer and GlaxoSmithKline.
Sagar currently works as a Global Marketing Manager at BD wherein his responsibilities entail understanding clinician needs in the acute care segment as well as developing pre-fillable syringe solutions to most closely address those needs.
Sagar holds a MBA from Texas Christian University, USA and also a Bachelor’s in Electrical Engineering from National Institute of Technology, India.
In the past 10 years within Flex Tommaso Borghi led R&D teams through the development of connected devices for top medical devices and pharmaceutical companies working in close collaboration with marketing departments, top design firms and production sites around the world. He created partnerships with Italian universities and led programs with European research centers to bring cutting-edge technologies into the market. He holds several patents and published research papers in international peer-reviewed journals. Tommaso holds a PhD in Electrical Engineering from Politecnico di Milano and worked as Visiting Scientist at the Massachusetts Institute of Technology on the development of Brain Machine Interfaces.
Laurence BOURETis a waste management expert for 15 years. She started her career in the public sector (local authority) before joining the car industry. She dedicated 5 years to her children before developpingalongside Jacques PELISSARD, former MP and former President of the French Mayor’s Association, the first national resource center for Waste Management. Since 2013 she manages a unique and pecular nonprofit EPR program called DASTRI. Financed by the health industry and approved by 3 Ministries, DASTRI is a network of 18000 collection points (mosly pharmacies) offering to homecare patients a safe solution for their sharps*.She is also a member of the National Commission for EPR programs in France and has engaged a long term thinking with all stakeholders about the future of EPR programs facing challenges such as the move toward ambulatory care or the development of connected medical devices. * Since 2013 DASTRI has distributed 10 Mio of sharp containers and collected 4 billion of used medical devices
1982 Diplôme de pharmacien option Biologie, Paris X
1986 Installation officine Bernay 27300.
1989 Election au CROP - Conseil Régional Ordre des Pharmaciens- de Haute Normandie
1991 Fondateur de Pharma Référence (Groupe PHR), groupement de pharmaciens d’officine
Directeur Général du groupe PHR.
1998 Expert auprès de l’Afssaps: Commission Nationale de Matériovigilance et commission AMM
GT CPD - Expert auprès de l’ANAES et DHOS, groupe : Chimiothérapie à Domicile.
Fondateur et Président d’HOPADOM, réseau des professionnels de santé pour les malades à Domicile, de Haute Normandie
2001 Président du CROP de Haute Normandie. Membre du bureau du Conseil Central de l’Ordre des Pharmaciens d’officine. CCA.
2003 Expert auprès de l’INCA : Chimiothérapie à domicile.
David Braun est responsable mondial de la solution d'affaires de dispositifs médicaux pour Merck Healthcare. David est un dirigeant qui compte 20 ans d'expérience en recherche et développement, en opérations, en stratégie et en gestion d'entreprise, travaillant en Europe, aux États-Unis et en Asie, dans des start-ups et de grandes multinationales. Au cours de sa carrière, David a acquis une expérience significative en concevant des organisations gagnantes, en dirigeant et en encadrant des équipes inter-fonctionnelles qui apportent des produits innovants de l'idéation au lancement. David est actuellement administrateur de Cellect, une start-up de biotechnologie active dans le domaine des cellules souches et des dispositifs médicaux.Avant de rejoindre Merck, David a occupé le poste de responsable des opérations et de la R & D globale de l'unité Technologie de Newell Brands, une société du classement Fortune 500, où il a dirigé des initiatives de croissance clés et des projets multimillionnaires.Avant cela, il a travaillé comme vice-président de R & D et Opérations chez Biosafe SA, une société de dispositifs médicaux récemment acquise par GE, développant et commercialisant des produits dans le domaine des banques de cellules souches et des thérapies cellulaires. Auparavant, David a également occupé divers postes de direction et d'ingénierie dans l'industrie de l'aérospatiale et de la haute technologie.David est titulaire d'une maîtrise en physique appliquée de l'Université Louis Pasteur et d'un diplôme en ingénierie électro-optique du Jerusalem College of Technology. Il a participé à des programmes deleadership exécutif et de gestion générale à la Harvard Business School et à l'IMD.
Iryna Bursuk is the Chief Operating Officer of the data science company StartUsInsights. Since 2014, Iryna has been scaling StartUs Insights’ operations in Austria (HQ), Ukraine and India. Together with her teams of analysts, data scientists and visualization experts, she provides actionable insights into startup-driven innovation for the industry leaders worldwide.
Anil Busimi a débuté sa carrière professionnelle chez SCHOTT AG en Allemagne en 2003. Il a occupé différents postes: développement des affaires, chef de projet et consultant en stratégie d'entreprise. En 2005, il a rejoint les activités de SCHOTT Pharmaceutical Packaging et a joué un rôle clé dans la Stratégie commerciale à long terme avec une bonne compréhension des tendances du marché, des besoins des clients et du paysage concurrentiel. Il a plus de 10 ans d'expérience dans la gestion de produits et l'innovation. D'août 2009 à juin 2016, il a occupé divers postes dans la gestion de produits mondiale pour les postes préremplissables. entreprise spécialisée dans les seringues, y compris les solutions PFS sur verre et polymère. Il fait actuellement partie de l’équipe stratégie et innovation en tant que chef de produit mondial senior pour les cartouches et dirige le lancement du marché de la plate-forme iQ ™. Il est un orateur professionnel lors de nombreuses conférences et séminaires sur des emballage primaire et dispositifs d'administration de médicaments.
Il est titulaire d'un M.Sc. diplôme en agriculture et génétique et MBA.
Giana Carli Lorenzini has a PhD in Packaging Logistics from Lund University, Sweden, where she now works as a postdoctoral research fellow. In her research, Giana has investigated the complexities that surround the industry processes of innovating and designing inclusive pharmaceutical packaging. Importantly, in an aging world, it is of utmost importance to provide people with pharmaceutical packaging that enables the patient to correctly administer and follow their treatment. In her talk, she will address main findings of research about the challenges and opportunities in the pharmaceutical and packaging industry to design and innovate packaging that can result in better care and better patient outcomes.
Je suis pharmacien et travaille au Leem depuis plus de 20 ans dans le domaine de la qualité pharmaceutique, après deux types d’expérience professionnelle, dans une entreprise pharmaceutique d’une part et au Ministère de la Santé puis à l’Agence du Médicament d’autre part. En tant que Directeur des Affaires Pharmaceutiques, je supervise les activités réalisées dans des domaines variés tels que les affaires règlementaires qualité, la bioproduction et le biodéveloppement, la gestion des sites pharmaceutiques et les activités du pharmacien responsable ; j’assure l’interface entre l’industrie pharmaceutique et les autorités de santé nationales, et particulièrement l’inspection de l’ANSM ou le Ministère de la Santé. Par ailleurs, je travaille régulièrement avec les autres associations.
Michelle has 15 years’ experience working in the environmental compliance sector building an extensive knowledge of the industry. After graduating from Cardiff University in 2002, she has developed her career by specialising in product stewardship, producer responsibility programs and their impacts on the producers.Co-Founding Lorax Compliance Limited in 2014, Michelle supports a diverse range of businesses with specialist Extended Producer Responsibility (EPR) reporting services as well as tailored consultancy covering all aspects of this environmental legislation. The award-winning solutions offered by Lorax Compliance improve methods of data management, provide comprehensive knowledge and present complete transparency into the costs of EPR compliance. EPR is a frequently changing and growing global field illustrated by increasing complexity and cost. Michelle’s focus within Lorax is to promote and simplify the vast range of reporting requirements their clients find themselves obligated by.
Andrew leads the development of Portal's disposable system. His background in electromechanical systems as well as high-volume mechanical devices supports Portal in the development of a scaleable system. Previously, Andrew was the first engineering hire at Fractyl, a surgical startup that he saw through first-in-human clinical testing. Prior to Fractyl, Andrew was at Cambridge Consultants where he developed drug delivery products for clients ranging from startups to large pharmaceutical companies. Andrew has a BS in Mechanical Engineering from FW Olin College of Engineering.
Dr Cole gained his PhD in Solid State Physics of Giant Magnetoresitive Materials grown by Molecular BeamEpitaxy at the University of Leeds in 2004. He then went on to work for Narec, the UK’s NationalRenewable Energy Centre in the Photovoltaics division where he initially worked as a Process Technologistand later a Business Development Manager. During this time, Dr Cole was part of the team responsible fora world record in photovoltaic conversion efficiency for multicrystalline solar cells. Subsequently, whenfaced with a change in government priorities and a reduction in funding for Photovoltaics, Dr Cole led aprocess of inward investment from a Swedish Greentech company leading in the separation of the Narecphotovoltaics division into a separate company, Narec Solar. Dr Cole was appointed Managing Director ofthis company. Dr Cole then went on to work as Chief Scientist at PolyPhotonix, leading a team of 5 scientists to developorganic light emitting technology for a wearable device that provides sight saving retinal treatments. Thedevice is now available commercially in a number of countries.At the start of 2017, Dr Cole moved to CPI and is working within the Strategic Marketing team within theremit of printable electronics for smart supply chains and smart pharmaceutical packaging. He recently ledan initiative to understand the capability requirements for a centre of excellence in smart pharmapackaging. He is currently leading the CPI Strategic Marketing Smart Packaging Initiative and is keen to helpsupportthe development and scale up of innovations that will improve supply chains, reduce wastage andimprove patient outcomes.
Pari is a senior innovation professional, who specialises in identifying, building and validating newopportunities for major global companies and emerging start-ups. He has 10 years of experience of leading innovation and strategy projects for many of the world’s largest medical device and pharmaceutical companies, with a focus on discovering opportunities through user, market and technology insights. Project have included the development of broad biosimilar defence strategies, the development of disruptive propositions from unmet clinical needs and IP landscaping activities to identify white spaces in crowded areas. He has worked within consulting and corporateenvironments, with a focus on understanding the issues in the “real-life” implementation of new opportunities for innovation. Pari has additionally led innovation and strategy programmes in multiple other industries,including FMCG, consumer health, drug delivery, surgical and critical care; specialising in lifesciences and diagnostics. Through these wide-ranging experiences, he has created and used manydifferent tools for innovation, to capture the lessons learned and to enable the efficient discovery ofboth innovative and robust new offerings in different markets.By background, Pari has a BSc in Biochemistry and a PhD in Genetics, with a specialism in thecommercialization of early-stage technologies.
Diplômée pharmacien en 1989, elle s’est engagée vers la pharmacie hospitalière et a été nommée Praticien Hospitalier en 1995. Elle a exercé en tant que Chef de Service et assuré la gérance de la pharmacie de l’hôpital Tenon entre 2009 et 2014. Elle assure désormais la responsabilité du département Médicament de la pharmacie du Groupe Hospitalier des Hôpitaux Universitaires de l’Est Parisien regroupant Saint Antoine, Tenon, Trousseau, Rothschild et Laroche Guyon. Engagée dans un Diplôme d’Etudes Approfondies d’éthique médicale et biologique en 1994, elle a poursuivi son travail de recherche autour des recommandations médicales et du bon usage du médicament notamment en cancérologie. Une partie de ses travaux ont fait l’objet de sa thèse d’Université soutenue en 2002 et elle est l’auteur ou le coauteur de 24 publications internationales. Elle continue depuis à s’impliquer et à impliquer son équipe dans l’évaluation des pratiques professionnelles et le développement de méthodes innovantes en s’appuyant sur le partage d’expérience et la recherche d’efficience. Ses thématiques de recherche actuelles concernent plus particulièrement la sécurisation de la prise en charge médicamenteuse et le développement de la pharmacie clinique.
Au sein de SANOFI, David Dronneau a été impliqué pendant plus de 20 ans dans le département informatique dans les premières soumissions électroniques de dossiers (NDA) et sur les essais cliniques électroniques avant de se tourner vers la mise en place de processus d'innovation. Depuis 4 ans, il rejoint le département Fournitures Cliniques en tant que responsable Technologies, Innovation et Solutions Procédés avec un objectif principal: Développer des emballages innovants répondant aux besoins des patients selon trois axes: Assurer la sécurité des patients, améliorer l'usage et améliorer la compliance des patients tout en assurant la continuité des opérations en termes de développement de solutions et de processus et enfin en assurant la diffusion des bonnes pratiques d'excellence en affaires (LEAN) dans l'unité.
Pascale Farjas is the Global Category Manager for the ENT (ear, nose, and throat) segment at Nemera, a leading developer and manufacturer of healthcare packaging and devices. Her role encompasses understanding patients’ needs and regulatory requirements to develop and market packaging solutions that improve the patient experience. She is in charge of the market introduction of new pump platforms for nasal
sprays. Pascale joined Nemera in 2011 and holds a chemical engineer degree from the National Institute of Applied Sciences of Rouen in France, completed with a marketing-focused Master Degree from the Business Administration Institute (France).
Martin Folger is currently (since September 2018) Head of Risk Management Sciences, Compliance and Quality within the global function Pharmaceutical Sciences at Boehringer Ingelheim Vetmedica GmbH. He is a pharmacist and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig, Germany. After starting his career working in pharmaceutical manufacturing of oral solid dosage forms for two years for a major US-based pharmaceutical company, he joined the Animal Health business of Boehringer Ingelheim in 1997 as a manager in formulation development. From 2002 until September 2018 he was Head of Global CMC Development Pharmaceuticals and responsible for all CMC-related activities including e.g. packaging development. He currently also has the role as the Qualified Person for investigational veterinary product.
Stéphanie Francart a rejoint VCLS en août 2018. Elle participe à la préparation des stratégies de réglementation des dispositifs médicaux et des activités opérationnelles - des premières phases de développement à la préparation des dossiers techniques et à la surveillance médicale post-commercialisation. Avec plus de 13 années de pratique dans le domaine des technologies médicales, notamment auprès de l'autorité compétente française ANSM et de l'organisme notifié GMED, Stéphanie a acquis une expérience couvrant les différentes phases du cycle de vie des dispositifs médicaux.
Chris Franzese is Clinical Leader at Matchstick. He manages a team of clinicians supportingclient projects related to combination product and medical device development and usabilitytesting, leads the company’s clinical
Page 3of 11training, and is accountable for making clinical knowledgeaccessible and relevant to client projects. An experienced clinical trial researcher, Dr. Franzesehas numerous peer-reviewed publications related to usability research for connected medicaldevices, antiplatelet therapies in coronary artery disease, and clinical laboratory testing. He hasa BS in Biology from Loyola University, an MHS in Health Informatics and a PharmD both fromFairleigh Dickinson University. He is a licensed pharmacist.
Andy is the founder of Cambridge-based Team Consulting, an award-winning medical device design and development consultancy. Andy is a mechanical engineer by profession, with over 25 years’ experience in medical device development. He has played a leading role in developing Team’s drug delivery business, both in technology development and in development of partner relationships. With a background in materials processing and manufacturing automation, he is committed to transferring best practices from manufacturing industry to the pharma and medical sector. An active member of industry associations including the PDA and Aerosol Society, he is also a UK accredited expert serving on the ISO committee developing standards for parenteral delivery devices.
Dr Pascale Gauthier est pharmacien(D.Pharm), elle a obtenu une maîtrise en biopharmaceutique (nouvelle méthode de gélification), une maîtrise spécifique (DEA) en pharmacocinétique (étude pharmacocinétique sur les médicaments hypertensifs ...) et un doctorat en technologie pharmaceutique (processus de rotogranulation)pour la fabrication des sphères) au sein del'Université d'Auvergne. Elle est en charge des cours de Marketing et Design à la Faculté de Pharmacie de Clermont-Ferrand et a participé à plusieurs brevets, publications internationales et conférences. Ses recherches ont porté sur les formes de libération modifiée, la conception pharmaceutique et les catégories d'utilisateurs, le numérique dans le domaine de la santé et elle a été invitée dans divers événements internationaux (Stratégies de formulation de médicaments, Pharmapack, ADF, PCD, Glatt Technology Training Centre). (WorldPack, Pharmapack, CPhI).
Pr Anne Gayot, Pharmacist, co-charge of the Pharmaceutical Industry Laboratory at the University of LILLE-France, member of the French Pharmaceutical and Generic working group of ANSM
Professor Anne GAYOT is in co-charge of the Pharmaceutical Industry Laboratory at the University of LILLE-France.This laboratory, beyond its teaching activities in the field of the development and production of pharmaceutical products, studies the solid state properties and properties of the particulate solid of the raw materials used in the formulation of drugs.It studies the physical properties of excipients and active substances with respect to functionnality characteristics.Professor Anne GAYOT was until reorganisation of the french agency member of the French Marketing authorization committee She is now member of the French Pharmaceutical and Generic working group at the French Agency. She participates to the writing of the guideline on Pharmaceutical Development of Medicines for Paediatric Use. She is the chair of the Functionnality Group related characteristics of the European Pharmacopoeia.She prepared her phD at the University of Lille (1981). It concerns microcapsules of activated charcoal for renal patients.Her scientific work concerns chacterisation of solid particles, extrusion-spheronisation, powder for inhalation. She is in charge of the master in industrial pharmaceutics.
Scott Gibson was recruited to Amgen in 2012 to build Amgen’s Advanced Device Technologies and Innovation Organization and since 2016 heads Amgen’s Device Technologies Innovation Center in Cambridge, Massachusetts. These organizations are responsible for identification and advancement of device technologies with application to Amgen’s product and portfolio strategies. Scott previously directed development for multiple drug delivery companies in treatment of diabetes, spasticity, and chronic pain resulting in acquisition by Medtronic and Boston Scientific. Scott earned his Bachelor's degree in Mechanical Engineering from California Polytechnic State University, San Luis Obispo, and currently holds 29 US patents in drug delivery and cardiac rhythm management.
Daniele a plus de 10 ans d'expérience dans les domaines de la fabrication pharmaceutique mondiale et de la chaîne d'approvisionnement. Il a occupé des postes avec une responsabilité croissante dans plusieurs endroits en Europe. Chez Abbott Laboratories, il a amélioré son expertise en approvisionnement et ses connaissances pharmaceutiques tout en étant basé dans une usine de fabrication en Italie, dans les bureaux divisionnaires de Londres et de Dublin ainsi qu'au siège de Bâle.
Daniele a rejoint le siège de Ferring près de Lausanne (CH) en octobre 2013 en tant que Global Category Manager, en charge de la stratégie d'achat globale et de son exécution pour les principaux matériaux d'emballage et dispositifs médicaux utilisés dans Ferring Finished Products.
Daniele a été nommé responsable des achats, des solides et de l'emballage en février 2017 et directeur de l'approvisionnement direct des produits en novembre 2017.
Daniele a une maîtrise en génie industriel de l'Université de Rome, en Italie, suivie d'un MBA à l'UCD Michael Smurfit Graduate Business School, à Dublin, en Irlande.
Carolin Grandt studied industrial engineering at the Cooperative University of Baden-Württemberg in cooperation with TSS Germany. From 2010, she worked in various functions in sales before she switched in 2015 to TSS Stein am Rhein/Switzerland as Product Manager. In this function, she manages and coordinates customer projects in the area of LSR and LSR-two-component parts together with the customers, the engineering team and the sales department. Since 2017, she is also in charge of the Commercial Department at TSS Stein am Rhein, which includes Product Management, Customer Service, Purchasing and Production Planning.
Paul heads up Team’s design group, working closely with clients and colleagues to improve the user experience of medical devices through design. Paul is a passionate advocate of the importance of ‘design thinking and is involved in all stages of product development, from front-end innovation to detailed design for manufacture.
During his time at Team, Paul has led the design and project management of many innovative products including inhalers, injectors, surgical instruments, diagnostic platforms, child resistant packaging and consumer medical products. He is particularly focused on ensuring the right direction is set from the outset, that user needs are thoroughly understood and represented throughout.
Currently Business Development Director at BIOCORP, in charge of seeking partnerships with pharma
companies or disease management platforms to customize BIOCORP’s existing range of connected
devices in the fields of injection and respiratory, and exploring opportunities for on demand programs.
Before joining BIOCORP, he was a consultant for a firm specialized in Healthcare. He also worked in the
pharma industry for Sanofi, and in the health insurance sector at AXA. In terms of academic background,
he graduated from HEC, a European business school, with a major in strategy. He also has a degree in
political sciences and public affairs
Pharmacien spécialisé en Affaires réglementaires, accès au marché et remboursement des technologies médicales innovantes, il accompagne ces entreprises sur le marché français et à l’international.
Après un début de carrière comme Enseignant-chercheur universitaire, il a intégré l’industrie pharmaceutique puis le monde des Dispositifs Médicaux, au sein d’entreprises internationales et d’associations professionnelles, où il a exercé différentes fonctions de management, notamment en Recherche & Développement, Affaires Réglementaires, Assurance Qualité et Accès au marché ainsi qu’en Evaluation médico-économique.
Mr. Hiroki Hasegawa is a researcher of Advanced Business Development Division.
He gained a Diploma in Science in 2013 and a Master Degree of Science in 2015 from Osaka University.
Since April 2015 he has been working for Mitsubishi Gas Chemical Company, Inc.
and in charge of macromolecular science, especially in composition development of thermosetting resin.
Since 2018 he has joined a development team of multilayer plastic vial & syringe for biologics.
After being graduated as a veterinary surgeon from the National Veterinary School of Toulouse, and some years being a practitioner and assistant in Parasitology, Bertrand Havrileck starts its career in the pharmaceutical industry in regulatory affairs and pre-clinical and clinical development. After some years in Bayer Pharma animal health then in Merck Sharp & Dohme, he joined Virbac Animal Health, where he headed successively regulatory affairs, pharmaceutical R&D, Europe R&D (Regulatory Affairs, Pharmaceutical R&D, Biological R&D) and since 2015 the Corporate Pharma R&D with 200 people. As part of the group of people in charge of Product Innovation in Virbac, his research interests include innovative packaging development dedicated to better use of the medicinal products i.e. ergonomy, safety, compliance, stability, ecology. He created a R&D packaging development group within the Corporate Pharma R&D dedicated to the development of new and innovative packaging resulting in 3 Pharmapack awards and 2 patents.
Samira Jafari is the head of Innovation department in Sulzer Mixpac. She holds a PhD degree in Mechanical and Fluid Engineering from ETH Zürich and has been with Sulzer Mixpac since 2014.
Sulzer Mixpac (part of Sulzer’s Applicator Systems Division) is a leading global company in the field of functional packaging and fluid applications and provides future-oriented products and innovative services for the application, mixing and delivering of liquids. Mixpac develops and manufactures plastic products, assemblies and devices for wide range of applications and industries ranging from dental and healthcare to manufacturing and renewable energies. Its strength is the creativity in the development and offering of new products and solutions with the highest quality.
Christa is the Director of Global Product Management, Prefilled Systems and Delivery, at West Pharmaceutical Services, Inc. Christa holds a diploma in Biomedical Engineering from the University of Aachen. She has worked within the pharmaceutical industry for more than 20 years. Christa gained experience as Quality Assurance Manager in one of the world’s leading pharmaceutical companies in sterile filling and packaging. In addition, she spent several years with the leading prefillable syringe manufacturer in the Customer Quality Assurance department. She joined West in 2005 and developed an expertise in prefillable systems and delivery technology in the Technical Customer Service and Marketing departments. Christa has held her current position since 2016.
Lionel Jeannin est Ingénieur Arts & Métiers ParisTech avec un Master en Business Administration de l'IAE d'Aix-en-Provence. Il possède plus de 17 ans d'expérience dans le secteur des dispositifs médicaux et des produits pharmaceutiques. Il a occupé des postes de gestionnaire de projet et de chef d'équipe de développement dans les domaines suivants: génie industriel, appareils médicaux pour la chirurgie oculaire, nutrition parentérale et produits pharmaceutiques OTC / Rx. Il a pris la responsabilité globale du développement de l'emballage pour OTC Brands comme Voltaren, Nicotinell et Fenistil et est actuellement en charge des projets Device & Packaging Development pour les nouveaux médicaments par voie orale chez Novartis Pharma AG. Il est également membre du réseau e-Device / Digital Development de Novartis Pharma Drug Delivery.
Sustainability Manager at Amcor Flexibles Europe Middle East and Africa, Isabelle JENNY holds an engineer degree in polymer chemistry from the University of Pierre and Marie Curie in Paris and a PhD in Polymer Chemistry.She has been with Amcor since 2003 as a packaging development engineer and then as sustainability manager. Isabelle has more than 15 years’ experience inlife cycle assessment and eco-design study in the food, pharmaceutical and medical flexible packaging market.She has also an expertise in sustainable sourcing, on biodegradable and compostable packaging and on flexible packaging recyclability.She is involved in the several EU initiatives like: -CEFLEX project were the objective is to at drive development of recycling options for flexible packaging in Europe (also building on the U.K.-focused REFLEX project)-EU PEF Wine Pilot were the objective is to develop a robust and science-based methodology to measure the environmental performance of wine products from a cradle–to-grave perspective, and appropriate solutions to communicate the life cycle environmental performance of wines -ASI (Aluminium Stewardship Initiative) were the objective is to implement Responsible Aluminium within Amcor Flexibles Europe Middle East and Africa
Adam Kalbermatten serves as Global Director of Marketing at Terumo. He isresponsible for overseeing the Terumo Pharmaceutical marketing team that developsand markets drug delivery devices and combination products to meet the unique needsof pharmaceutical companies. Prior to joining Terumo in 2015, Adamheld variousoperations and commercial leadership roles at both Becton Dickinson (BD) and Merck.Adam holds a Bachelor of Engineering in Mechanical Engineering and a Masters ofEngineering in Engineering Management from Stevens Institute of Technology andaMBA from Columbia University.
A passionate individual with extensive experience in Operations, Engineering & Supply Chain
dedicated to supporting the United Nations Sustainable Development Goals by influencing and
directing industries through the deployment and utilization of enabling technologies.
Teddy is Mechanical Engineer graduated from the Engineer School “Institut Catholique d’Arts et Métiers” in France. He also has a Master Degree in Mathematics.
Teddy has worked first in Automotive (Arvin Meritor) and Energy (GE) fields. Then he joined the pharmaceutical industry as a consultant for Big Pharma companies like AstraZeneca, Fareva or Cephalon mainly for Lean Manufacturing implementation.
Teddy joined Sanofi Pasteur 10 years ago in Manufacturing Technology department first, then he moved to Global Engineering department as Technology Program Manager, where he is now leading the Primary Containers Identification Program.
Teddy has a strong and extensive expertise in pharmaceutical Filling & Packaging and is supporting different industrial projects related to Datamatrix coding, anti-counterfeiting measures and new packaging implementation.
Holger Krenz isresponsible for the European customer activities to support the commercialization of SiO2 ?sproduct portfolio. He is a biologist with a focus on Neurophysiology working for the last 16years in the medical device industry in various positions including R& D project management aswell as sales and business development at different companies e.g. Boehringer Ingelheim andWestRock / Silgan Dispensing. In 2014 he joined SiO2 Medical Products to support and managethe European customer activities.
Dr. Mark Lee is the Chief Technology Officer for the Health Solutions group at Flex Ltd. where he drives innovation and excellence within the medical business, focusing on Sketch-to-Scale™ solutions. This extends from defining user needs through human-factors through innovation and design, to ramp up, full scale production, and supply chain management. Prior to Flex, Dr.Lee was the Global Head of R&D for J&J where he led research and development activities across the pharmaceutical, medical device and consumer health segments of the company. Dr.Lee also held leadership roles in R&D with fortune 100 medical device companies including Baxter, GE medical and Amgen, where he developed the combination product design process for all of Amgen’s pipeline molecules.
Dr. Lee holds a PhD in Engineering Science from the University of Western Ontario, Canada and a Master of Science, and Bachelor’s Degree in Engineering Science from the University of Toronto, Canada.
Lionel is R&D Associate Director at BD responsible for Design, Development and Life Cycle Management activities for Autoinjectors and Safety solutions. Lionel joined BD in 2005 and held roles of increasing responsibilities within R&D. He has a deep experience in Drug Delivery Systems Design and Development from Innovation stage to commercialization. He developed in particular BD Physioject™ Autoinjector and is listed in many patents.
Prior to BD, Lionel worked in the Automotive Industry. He has a Master’s Degree in Engineering with a specialization in plastic parts design and manufacturing.
William Matakas has worked within the pharmaceutical industry for over 15 years in areas of process engineering, operations and marketing. Currently in his role as Sr. Director, Product Management, Vial Containment & Delivery at West Pharmaceutical Services, William is responsible for defining new market requirements, launching new products, supporting business development plans, and overall execution of global marketing strategies for West.
After finishing his studies in biology, Dr Novak completed his PhD in physics at the Max-Planck-Institute for Neurochemistry in Munich. He has held many leadership roles in research firms, biotech, and pharmaceutical equipment and packaging. In September 2018 he returned to Gerresheimer in a new global senior role for business development. Dr Novak’s focus has always been to improve the knowledge base of processes and discover new ways to optimize pharmaceutical processes based on scientific thinking which will serve the market needs.
Delphine Pernot est diplômée ingénieur agronome d’AgroParisTech et titulaire d’un Mastère en ingénierie et gestion de l’environnement à l’ISIGE Mines Paristech (2009). Elle débute sa carrière chez Airparif avant d’intégrer, en 2010, le cabinet Deloitte en tant que consultante puis manager Développement Durable.Sept années plus tard, Delphine Pernot rejoint l’équipe commerciale d’Adelphe. Sa missionest de construire une relation partenariale avec les clients et les parties prenantes issus principalement du secteur pharmaceutique notamment autour de l’éco-conception des emballages et accompagnement des entreprises dans leur stratégie RSE.
Mathieu Quintin a rejoint VCLS en 2016 et travaille sur des projets impliquant la conception et la mise en œuvre de stratégies réglementaires et cliniques pour des dispositifs médicaux innovants. Mathieu assiste les start-ups, les PME et les entreprises internationales depuis les premières phases de développement jusqu'à l'enregistrement sur le marché, y compris les plans de développement clinique mondiaux, les stratégies de soumission d'applications d'essais cliniques en Europe, les interactions avec les organismes de réglementation (organismes notifiés et autorités compétentes en matière de santé), l'assistance à la préparation de dossiers techniques. et soutien aux activités relatives aux dispositifs médicaux post-commercialisation.
Dr Joël Richard is currently Head of Technical &Pharmaceutical Operations at MedinCell (Montpellier, France). He is leading all the pharmaceutical development and non-clinical pharmaco/toxico-kinetic activities of the company, specialized in the development of Long-Acting Injectables. (LAIs), using theproprietary technology BEPO®. Dr Richard has 30 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various Biotech and Pharma companies, such as: -Senior Vice President, Pharmaceutical Development –Peptides in Ipsen (France),-Vice President, Drug Product Development in Ipsen (France),-Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany),-Vice President Research, and Europe R&D Director at Ethypharm (France),-COO atMainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems. Since 1996, Dr Richard has focused his research activity on new formulation technologies and drug deliverysystems (such as microspheres, nanosystems, gelling systems, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. Dr Richard has graduated from Ecole Normale Supérieure (Cachan, France). He has got a PhD in Materials Science from University of Paris, France, and the “Habilitation à Diriger les Recherches” degree in Chemistry from University of Bordeaux I. He has published 68 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery systems, supercritical fluids, protein formulations, nanoparticles, etc.). He is the author of more than 140 international communications and 55 patent families.
Mathias Romacker est Senior Director, Device Strategy chez Pfizer à New York. Il a rejoint Pfizer en mars 2015. Dans ce rôle au sein de Pfizer Global Supply, il se concentre sur la partie frontale de la technologie des appareils. Il travaille avec de multiples fonctions et sites à travers l'organisation pour développer une stratégie de dispositif pour les produits en ligne et en ligne de Pfizer.
Auparavant, Mathias a travaillé plus de 9 ans dans le secteur des appareils pour Amgen à Thousand Oaks, en Californie.
Avant de rejoindre Amgen, il a occupé plusieurs postes de vente et de marketing chez Becton Dickinson et Gerresheimer en Allemagne, en Afrique du Sud et au New Jersey.
Mathias est titulaire d'une maîtrise en économie de l'Université de Fribourg / Allemagne.
Guilhem Rousselet has been in charge of Global Packaging for Sanofi Group for the last 5 years, and is leading the serialization project for Sanofi.
Page 7of 11Before joining Sanofi, he had several experiences in Packaging Development in mass market companies in home care and cosmetics.
Fabien Roy's practice focuses on European Union (EU) and national regulatory matters involving pharmaceutical, and medical device laws and guidelines. He has developed close contact with relevant government authorities in these sectors. Fabien is a keen writer and regularly publishes articles concerning developmentsin the medical device and pharmaceutical sectors. He is also a regular speaker at dedicated conferences.Fabien focuses particularly on the different stages of the medical device CE marking process. He advises on a wide variety of topics which include thefollowing: determination of the appropriate classification of individual products; clinical investigation procedure (e.g. authorisation from the EU Member States competent authorities, opinion from Ethics Committee, amendment to the Protocol, informed consent, serious adverse event qualification and notification, handling of personal data); drafting of clinical investigation and clinical trial agreements, distribution agreements and contract manufacturing agreements; clinical evaluation; conformity
Page 4of 11assessment procedure; review of Instruction For Use, products' labelling and promotional material including websites; post-marketing surveillance activities including the notification of adverse event, product recall or product withdrawal; reimbursement. Fabien also advises on questions regarding marketing authorisation procedures, variation procedures, and clinical trials, promotional and marketing activities in the pharmaceutical sector.Fabien joined Hogan Lovells International in 2007 (at that time Hogan & Hartson LLP). He was called to the Brussels Bar in early 2011.
Christian Schierholz is Corporate Development Manager and Venture Associate at Sanner Ventures GmbH. Within the Sanner Group, Sanner Ventures aims to explore new business areas and is devoted to products and solutions that help protect patient health and facilitate patient engagement.
Christian has 10 years of business development and strategy experience and worked in the telecommunication, pharmaceutical and healthcare sector in Germany, South East Asia and the US.
Hans-Martin Schwarm, Ph.D., is Licenced Pharmacist, Certified Food Chemist, Pharmacist for Pharmaceutical Analysis, and Pharmacist for Pharmaceutical Technology. He has over 30 years of experience in pharmaceutical industry at various positions on senior and corporate management level for Quality Assurance and Quality Management, Technical Operations and Supply Chain, Regulatory, Product Development and Technology Transfer. He was with American Home (now Pfizer), STADA, and AET. He also served as Qualified Person and QP Pharmacovigilance, and was responsible for international project in Europe, US, India, and China. Today he acts as Senior Advisor Pharma and Health Care providing advanced solutions for the pharma and health care industry.
Sai Shankar is Director for Connected Devices Business Development at Aptar Pharma. Sai has 15 years of
product development and business strategy experience in the pharmaceutical industry. He joined Aptar
in April 2017, with previous stints at Allergan and Sanofi.
With 30 years of experience in the field of Medical Devices, In-Vitro Diagnostic and
Pharmaceutical Packaging, Pascal Sircoulomb has been holding sales, marketing and
management positions within large international companies (BD, Danaher/Leica) as well as
start-up biotechs. He has joined ARaymondlife in 2018 as Business Development Director.
Ger Standhardt is Executive Director of the Healthcare Compliance Packaging Council of Europe (HCPC Europe). HCPC Europe is a not for profit organisation. The mission of HCPC Europe is to educate the healthcare sector in the improvement of patients’ compliance by promoting packaging that improves patients’ lives. One of HCPC Europe’s key objectives is to achieve demonstrable improvements in patients’ lives, as well as enhanced compliance and adherence to medication regimens by facilitating knowledge sharing in the area of patient-friendly pharmaceutical packaging.
Ger studied Industrial Design Engineering at Delft University of Technology and graduated on the Airline Meal of the Future (March 2007), an application case for RFID in airline catering. Since his graduation he has been working at the NVC Netherlands Packaging Centre as manager Knowledge Development & Projects. He is responsible for the content of the training and educational activities, like the NVC Course Programmes in Packaging for middle and upper management, and for setting up and running new projects. He has been running the NVC Project Pharmaceutical Packaging Innovation since 2011. In this project NVC-members share innovative solutions with each other in order to come to improvements or new applications together. The main themes are accessible design, authenticity, and improving patient adherence.
On 1 July 2015 he took on the role of Executive Director of HCPC Europe. Running HCPC Europe is part of his current job at the NVC Netherlands Packaging Centre.
Yves Steffen has over 15 years of experience in the pharmaceutical industry. In 2004 he began his career for Cilag AG (a Johnson & Johnsoncompany) as project engineer for drug product manufacturing and visual inspection lines. In 2006 he joined Novartis and held there several positions in commercial manufacturing covering engineering, product launches / transfer and commercial product responsibilities for Biosimilars. Since 2014 his focus area was medical devices and combination products and since 3 years Yves Steffen is heading the commercialization group of medical devices and combination products including secondary packaging for Novartis.
Packaging Engineer graduated from former-ESIEC (now ESIREIMS), Packing and Packaging Engineer School from Reims, Arnaud Steiner evolves in this world of packaging since his beginnings. After 5 years in pharmaceutical industry for human health at AstraZeneca, on sites of Reims and Dunkerque, he continued for 10 years in the food industry at Hochland near Verdun.Since 3 years, he is now in pharmaceutical industry for animal health at Virbac, the 7th veterinary company worldwide, where he is head of primary packaging development in the Corporate pharma R&D department.
Dan-Ola Svenssonhas over 30 years of experience in the world of thermoplastics. Hespent the early years as quality engineer with a major injection molding company,serving the automotive industry and laid the foundation to his profound interest forquality management systems, Leadership for quality and quality improvements.While keeping his initial interest area, he moved further into the world ofcompounding of standard and engineering plastics, driving developments within thequality-and laboratory management systems.Furthermore, innovation became a key area leading to special raw material-andcompound solutions.He joined Clariant in 1997. After a position within quality-and laboratorymanagement, in 1999 Dan-Ola became technical manager for the Malmoe/Swedishmasterbatch manufacturing site, focusing on technical-and regulatory innovations ofprocesses, products and services. In 2010, in relation to Clariant implementing a dedicated medical-and healthcareorganization and the brand name of Mevopur, he became regional technical managerfor Europe within segment Healthcare Polymer Solutions.
Charbel Tengroth is an experienced professional having worked in various leader roles within the fields of aseptic drug product and process development, and medical devices and combination products. Charbel has a strong scientific background holding a PhD in physics from Chalmers Institute of Technology and a post-graduate research positions at Princeton University and AstraZeneca R&D, which has given him the ability to very quickly get to the core of complex issues. He is currently working as an independent consultant for the pharma industry within his field of expertise. Before starting his own company, Charbel was Technical Director at SHL Medical, a world-leading developer and manufacturer of medical devices. As Head of Device Development, Charbel managed multi-disciplinary teams of design engineers, human factor engineers, and industrial designers.Charbel came to SHL Medical from Pfizer where he managed a team of scientists working with process development and drug product characterization of aseptic and biological drug products, and medical devices (injectors, inhalers, and others). He also led several product technology transfers and was managing an aseptic formulation and filling pilot plant.Over the years Charbel has contributed to the success of a wide range of pharmaceutical products and medical devices such as Prevnar 13, Genotropin, Depo-Provera/Sayana, and the DAI and Molly families of injection devices.
Charlotte started her career as a Belgian business lawyer (corporate and commercial law). Triggered by the clients' businesses, she gained experience in international strategic sales & marketing within highly regulated environment e.g. pharma (Pfizer), medical devices (Medline, 3M) and sterilization (STERIS AST). Currently being commercial manager within STERIS AST, she is involved in business
development, managing teams, strategic decision making, contract negotiations and networking.
Dr. Kerstin Walke est responsable des produits biologiques pour le développement pharmaceutique chez Boehringer Ingelheim avec un doctorat en philosophie en chimie. Elle a plus de 17 ans d'expérience dans le domaine biopharmaceutique et dans la technologie et l'innovation. Après son stage, elle était responsable du développement corporatif de Biooharma. En 2011, elle a développé la technologie et l'innovation au sein du département biopharmaceutique. En 2015, elle est devenue responsable du développement pharmaceutique, en charge de la formulation, de l'emballage primaire et du développement de produits combinés.
Susanna White has worked as a Device Development Engineer at Oval Medical Technologies for thepast 6 years, where she is involved in the design and test programmes for their innovative polymericPDC. Much of her work has focused on the study of highly viscous and non-Newtonian drugformulations -using numerical modelling techniques in combination with experimental investigationin order to achieve the most appropriate delivery system for challenging formulations. Susannagraduated from the University of Cambridge with a Master’s Degree in Engineering for the LifeSciences.
Dr Gerallt Williams is Director Scientific Affairs at Aptar Pharma. After obtaining his PhD from the
University of Wales, UK in 1985, Gerallt has held various industrial positions at Monsanto Inc. (UK),
Fisons Ltd (UK), Valois (France) and Inhale/Nektar Therapeutics (USA).
Gerallt is now in charge of Scientific Affairs for the Aptar Pharma Prescription division, Le Vaudreuil,
France and is engaged in the development of new devices for nasal, inhaled and injectable drug
Jingwei ZHANG is currently R&D director of SGD Pharma, based in France.
Previously to this position, he worked for Saint-Gobain Group for more than 20 years, as strategic project manager and R&D portfolio manager. He has a large experience in glass products and glass process.
He is inventor of more than 70 international patents.
He is member of TC12 (Technical Committee 12 for pharma glass packaging) under ICG (International Commission on Glass).
Jingwei ZHANG graduated from Harbin Institute of Technology in China and received his Ph.D in France.